260 related articles for article (PubMed ID: 28980151)
1. Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).
Salen G; Steiner RD
J Inherit Metab Dis; 2017 Nov; 40(6):771-781. PubMed ID: 28980151
[TBL] [Abstract][Full Text] [Related]
2. Apparent underdiagnosis of Cerebrotendinous Xanthomatosis revealed by analysis of ~60,000 human exomes.
Appadurai V; DeBarber A; Chiang PW; Patel SB; Steiner RD; Tyler C; Bonnen PE
Mol Genet Metab; 2015 Dec; 116(4):298-304. PubMed ID: 26643207
[TBL] [Abstract][Full Text] [Related]
3. Chenodeoxycholic acid (CDCA) treatment during pregnancy in women with cerebrotendinous xanthomatosis (CTX): Lessons learned from 19 pregnancies.
Zaccai TCF; Hassin-Baer S; Kfir NC; Duell PB; Neerhof M; Sloma R; Roitman M; Kisanuki YY; Verrips A; DeBarber AE
Genet Med; 2024 May; 26(5):101086. PubMed ID: 38288684
[TBL] [Abstract][Full Text] [Related]
4. Genetically and clinically confirmed atypical cerebrotendinous xanthomatosis with normal cholestanol and marked elevations of bile acid precursors and bile alcohols.
DeBarber AE; Schaefer EJ; Do J; Ray JW; Larson A; Redder S; Fowler M; Duell PB
J Clin Lipidol; 2024 Mar; ():. PubMed ID: 38637260
[TBL] [Abstract][Full Text] [Related]
5. Cerebrotendinous Xanthomatosis, a Treatable Disorder Often Missed: Case Series of Three Patients Confirmed by Genetic Testing.
Yaqoob A; Dar WR; Raina A; Khuja Z; Chandra A; Bukhari I; Ganie H; Wani M; Asimi R
Neurol India; 2024 Jan; 72(1):138-141. PubMed ID: 38443015
[TBL] [Abstract][Full Text] [Related]
6. Familial variability of cerebrotendinous xanthomatosis lacking typical biochemical findings.
Guenzel AJ; DeBarber A; Raymond K; Dhamija R
JIMD Rep; 2021 May; 59(1):3-9. PubMed ID: 33977023
[TBL] [Abstract][Full Text] [Related]
7. Cerebrotendinous xanthomatosis with tremor as the main manifestation: A case report.
Zhao W; Han J; Tao D; Zheng H
Medicine (Baltimore); 2024 Apr; 103(17):e37976. PubMed ID: 38669366
[TBL] [Abstract][Full Text] [Related]
8. Clinical, biochemical, and molecular insights into Cerebrotendinous Xanthomatosis: A nationwide study of 100 Turkish individuals.
Zubarioglu T; Kıykım E; Köse E; Eminoğlu FT; Teke Kısa P; Balcı MC; Özer I; İnci A; Çilesiz K; Canda E; Yazıcı H; Öztürk-Hişmi B; Bulut FD; Dorum S; Akgun A; Yalçın-Çakmaklı G; Kılıç-Yıldırım G; Soyuçen E; Akçalı A; Güneş D; Durmuş A; Gündüz A; Kasapkara ÇS; Göksoy E; Akar HT; Ersoy M; Erdöl Ş; Yıldız Y; Hanağası HA; Arslan N; Aktuğlu-Zeybek Ç
Mol Genet Metab; 2024 Jun; 142(2):108493. PubMed ID: 38772327
[TBL] [Abstract][Full Text] [Related]
9. A useful multi-analyte blood test for cerebrotendinous xanthomatosis.
DeBarber AE; Luo J; Giugliani R; Souza CF; Chiang JP; Merkens LS; Pappu AS; Steiner RD
Clin Biochem; 2014 Jun; 47(9):860-3. PubMed ID: 24769274
[TBL] [Abstract][Full Text] [Related]
10. Cerebrotendinous xanthomatosis: clinical and imaging clues of a rare treatable cause of ataxia.
Magriço M; Cabral P; Bugalho P
BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35858741
[No Abstract] [Full Text] [Related]
11. Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis.
Duell PB; Salen G; Eichler FS; DeBarber AE; Connor SL; Casaday L; Jayadev S; Kisanuki Y; Lekprasert P; Malloy MJ; Ramdhani RA; Ziajka PE; Quinn JF; Su KG; Geller AS; Diffenderfer MR; Schaefer EJ
J Clin Lipidol; 2018; 12(5):1169-1178. PubMed ID: 30017468
[TBL] [Abstract][Full Text] [Related]
12. Early diagnosed cerebrotendinous xanthomatosis patients: clinical, neuroradiological characteristics and therapy results of a single center from Turkey.
Zubarioglu T; Kiykim E; Yesil G; Demircioglu D; Cansever MS; Yalcinkaya C; Aktuglu-Zeybek C
Acta Neurol Belg; 2019 Sep; 119(3):343-350. PubMed ID: 29058268
[TBL] [Abstract][Full Text] [Related]
13. Unique case of cerebrotendinous xanthomatosis revisited: All the mutations responsible for this disease are present in the CYP27A1 gene.
Jiao H; Olin M; Hansson M; Eggertsen G; Eriksson M; Angelin B; Björkhem I
J Intern Med; 2018 Jun; 283(6):604-606. PubMed ID: 29095540
[No Abstract] [Full Text] [Related]
14. Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use.
Kuriyama M; Tokimura Y; Fujiyama J; Utatsu Y; Osame M
J Neurol Sci; 1994 Aug; 125(1):22-8. PubMed ID: 7964884
[TBL] [Abstract][Full Text] [Related]
15. Natural history of neurological abnormalities in cerebrotendinous xanthomatosis.
Wong JC; Walsh K; Hayden D; Eichler FS
J Inherit Metab Dis; 2018 Jul; 41(4):647-656. PubMed ID: 29484516
[TBL] [Abstract][Full Text] [Related]
16. The safety and effectiveness of chenodeoxycholic acid treatment in patients with cerebrotendinous xanthomatosis: two retrospective cohort studies.
Verrips A; Dotti MT; Mignarri A; Stelten BML; Verma S; Federico A
Neurol Sci; 2020 Apr; 41(4):943-949. PubMed ID: 31863326
[TBL] [Abstract][Full Text] [Related]
17. Cholic acid as a treatment for cerebrotendinous xanthomatosis in adults.
Mandia D; Chaussenot A; Besson G; Lamari F; Castelnovo G; Curot J; Duval F; Giral P; Lecerf JM; Roland D; Pierdet H; Douillard C; Nadjar Y
J Neurol; 2019 Aug; 266(8):2043-2050. PubMed ID: 31115677
[TBL] [Abstract][Full Text] [Related]
18. Nationwide survey on cerebrotendinous xanthomatosis in Japan.
Sekijima Y; Koyama S; Yoshinaga T; Koinuma M; Inaba Y
J Hum Genet; 2018 Mar; 63(3):271-280. PubMed ID: 29321515
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
